Australia's most trusted
source of pharma news
Monday, 07 July 2025
Posted 7 July 2025 AM
CSL Behring has scored a win for the recombinant factor IX treatment which underpins its haemophilia segment, signing a contract with the National Blood Authority.
Idelvion, indicated in all patients with haemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, control and prevention of bleeding episodes, and control and prevention of bleeding in the perioperative setting, was included in the new haemophilia treatment supply arrangements.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.